tiprankstipranks
Advertisement
Advertisement
Atricure Faces Ongoing and Potential New Risks Despite No Changes to 2025 10‑K Disclosures
PremiumCompany AnnouncementsAtricure Faces Ongoing and Potential New Risks Despite No Changes to 2025 10‑K Disclosures
2M ago
AtriCure price target raised to $55 from $53 at Canaccord
Premium
The Fly
AtriCure price target raised to $55 from $53 at Canaccord
2M ago
AtriCure participates in a conference call with JPMorgan
Premium
The Fly
AtriCure participates in a conference call with JPMorgan
2M ago
3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts
PremiumMarket News3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts
4M ago
AtriCure Earnings Call Highlights Growth Amid Headwinds
Premium
Company Announcements
AtriCure Earnings Call Highlights Growth Amid Headwinds
4M ago
AtriCure: Underappreciated Moat, Growing Profitability, and Long-Term Upside in Underpenetrated Cardiac Markets
Premium
Ratings
AtriCure: Underappreciated Moat, Growing Profitability, and Long-Term Upside in Underpenetrated Cardiac Markets
4M ago
AtriCure downgraded to Perform from Outperform at Oppenheimer
PremiumThe FlyAtriCure downgraded to Perform from Outperform at Oppenheimer
4M ago
AtriCure price target lowered to $52 from $60 at Citizens
Premium
The Fly
AtriCure price target lowered to $52 from $60 at Citizens
4M ago
Closing Bell Movers: Palo Alto Networks down 8% on soft guidance
Premium
The Fly
Closing Bell Movers: Palo Alto Networks down 8% on soft guidance
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100